Results Adalimumab trough levels were recorded longitudinally for 336 ... The study protocols of the ADMYRA trial were approved by the Independent Ethics Committee or Institutional Review Board for ...

In November 2024, Skyrizi surpassed Humira as AbbVie's top seller; calls for PBM transparency and biosimilar access reforms ...

On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and ...

Learn about the new guidelines released by the AGA for pharmacological management of moderate-to-severe ulcerative colitis.

Notable news about inflammatory bowel disease (IBD) in 2024 included a study evaluating loss of response to tumor necrosis ...

Here are the year’s notable fiction, poetry and nonfiction, chosen by the staff of The New York Times Book Review. By The New York Times Books Staff An incisive new book, “How Sondheim Can ...

You will be able to get a quick price and instant permission to reuse the content in many different ways. Immunogenicity of adalimumab could impair important treatment outcome parameters in patients ...

Biosimilars demonstrate comparable drug survival and safety with adalimumab among new users, but patients switching from Humira (the originator product) to biosimilars had a 35% higher ...

Methods Prospective non-randomised observational study in patients with active erosive RA with inadequate response to methotrexate (MTX) receiving either tocilizumab (TOC) monotherapy or adalimumab ...

Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet syndrome, with adalimumab demonstrating a quicker response time ...

Join former prosecutor Andy McCarthy as he delves into the legal ins and outs of the latest Washington dramas with National Review editor in chief Rich Lowry. Capital Record – your weekly ...

Consumers say information found in customer reviews helps them choose trustworthy businesses. Businesses appreciate customer reviews because they highlight customer experiences. Just like ...